

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 March 2023 (23.03.2023)



(10) International Publication Number
WO 2023/042096 A1

(51) International Patent Classification:

A61K 38/47 (2006.01) A61P 37/00 (2006.01)
A61M 5/44 (2006.01) C07K 16/06 (2006.01)

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/IB2022/058670

(22) International Filing Date:

14 September 2022 (14.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/243,832 14 September 2021 (14.09.2021) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1 Doshomachi 4-Chome, Chuo-Ku, Osaka-shi, Osaka 541-0045 (JP).

(72) Inventors: **HOEFINGHOFF, Joris**; Guglgasse 8/2/38, 1110 Vienna (AT). **LEIDENMUEHLER, Peter**; Friedrich-Engels-Platz 15-16/1/26, 1200 Vienna (AT). **GANGADHARAN, Bagirath**; 26, Favoritenstrasse, 4B, 1040 Vienna (AT). **HAIDER, Norbert**; Loewengasse 11/9, 1030 Vienna (AT). **NAGY, Andras**; c/o Baxalta Innovations GmbH, Industriestrasse 67, 1220 Vienna (AT). **Li, Zhaoyang**; 75 Albemarle Rd., Newton, Massachusetts 02460 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE

(57) Abstract: Provided is a concentrated pharmaceutical formulation of an immune globulin (IG), and convenient methods for the subcutaneous administration of this pharmaceutical formulation in a warmed state. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are combinations, compositions and kits containing an immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration.

WO 2023/042096 A1